Were­wolf pre­pares to bare its teeth in 1st tri­al for tar­get­ed cy­tokine tu­mor fight­ers with new round of in­vestor cash

Boston area biotech Were­wolf Ther­a­peu­tics launched in late 2019 with the goal of chas­ing nov­el im­mune sys­tem mod­u­la­tors to erad­i­cate sol­id tu­mors. Just over a year af­ter hit­ting the ground run­ning, Were­wolf has three can­di­dates in de­vel­op­ment and has its eyes set on the clin­ic with a new round of fund­ing.

Were­wolf on Thurs­day un­veiled a $72 mil­lion Se­ries B round to move its im­munother­a­pies, which tar­get the mi­croen­vi­ron­ments of sol­id can­cer tu­mors, to Phase I clin­i­cal proof-of-con­cept stud­ies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER